Astute Inks Deal With Shanghai Fosun for Chinese Distribution of NephroCheck, $20M in Financing
Astute is working with Fosun on Chinese trials for the test that it will use to gather data for a submission to the Chinese Food and Drug Administration.
The company has no plans to position NephroCheck for long-term prognosis but said the findings bolster data supporting use of the test in the acute setting.
From research collaborations to corporate acquisitions, attention from the broader scientific community highlighted the field's capabilities and limitations.
NEW YORK (GenomeWeb) – Astute Medical said this week that it has received US Food and Drug Administration 510(k) clearance for its NephroCheck Test System, a protein biomarker-based test for assessing risk of acute kidney injury.